ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring-even in hands of ELISPOT-inexperienced investigators

Journal of Immunotoxicology

Volumn 6, Issue 4, 2009, Pages 227-234

  Zhang, W ^a   Caspell, R ^a   Karulin, A Y ^a   Ahmad, M ^b   Haicheur, N ^c   Abdelsalam, A ^d   Johannesen, K ^e   Vignard, V ^f   Dudzik, P ^g   Georgakopoulou, K ^h   Mihaylova, A ⁱ   Silina, K ^j   Aptsiauri, N ^k   Adams, V ^l   Lehmann, P V ^a,m   McArdle, S ^b  

^a Cellular Technology Ltd   (United States)

^b NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e Norwegian Institute   (Norway)

^f INSERM   (France)

^g JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^h SAINT SAVVAS HOSPITAL   (Greece)

ⁱ UMBAL Alexandrovska   (Bulgaria)

^j Biomedical Research Study Centre   (Latvia)

^k HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^l Onyvax Ltd   (United Kingdom)

^m CASE WESTERN RESERVE UNIVERSITY   (United States)

more..

Author keywords

CD8 cell immunity; Immune assay standardization; Immune monitoring

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; REAGENT;

ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELLULAR IMMUNITY; CLINICAL PROTOCOL; CONTROLLED STUDY; CRYOPRESERVATION; ENZYME LINKED IMMUNOSPOT ASSAY; EUROPE; HUMAN; HUMAN CELL; LABORATORY; MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REPRODUCIBILITY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UNITED STATES; VALIDATION STUDY;

ANTIGENS, VIRAL; CRYOPRESERVATION; CYTOMEGALOVIRUS; EUROPE; HUMANS; IMMUNOASSAY; INTERFERON-GAMMA; INTERNATIONAL COOPERATION; LABORATORIES; LEUKOCYTES, MONONUCLEAR; MONITORING, IMMUNOLOGIC; OBSERVER VARIATION; PHOSPHOPROTEINS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING; T-LYMPHOCYTES; UNITED STATES; VIRAL MATRIX PROTEINS;

EID: 70450211340     PISSN: 1547691X     EISSN: 1547691X     Source Type: Journal    
DOI: 10.3109/15476910903317546     Document Type: Article

References (12)

1. Britten, C. M., Janetzki, S., van der Burg, S. H., Gouttefangeas, C., and Hoos, A. 2007 Toward the harmonization of immune monitoring in clinical trials: Quo vadis? Cancer Immunol. Immunother. 57:285-288.
2. Britten, C. M., Janetzki, S., Ben-Porat, L., Clay, T. M., Kalos, M., Maecker, H., Odunsi, K., Pride, M., Old, L., Hoos, A., and Romero, P. 2009. Harmonization guidelines for HLA-peptide multimer assays derived from results of a largescale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol. Immunother. DOI 10.1007/s00262-009-0681-z.
3. Cox, J. H., Ferrari, G., Kalams, S. A., Lopaczynski, W., Oden, N., and D'souza, M. P. 2005. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res. Hum. Retrovirus. 21:68-81.
4. Currier, J. R., Kuta, E. G., Turk, E., Earhart, L. B., Loomis-Price, L., Janetzki, S., Ferrari, G., Birx, D. L., and Cox, J. H. 2002. A panel of MHC Class Irestricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Meth. 260:157-172.
5. Hesse, M. D., Karulin, A. Y., Boehm, B. O., Lehmann, P. V., and Tary- Lehmann, M. 2001. A T-cell clone's avidity is a function of its activation state. J. Immunol. 167:1353-1361.
6. Janetzki, S., Panageas, K. S., Ben-Porat, L., Boyer, J., Britten, C. M., Clay, T. M., Kalos, M., Maecker, H. T., Romero, P., Yuan, J., Kast, W. M., and Hoos, A. 2008. Results and harmonization guidelines from two largescale international ELISPOT proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol. Immunother. 57:303-315.
7. Kreher, C. R., Dittrich, M. T., Guerkov, R., Boehm, B. O., and Tary-Lehmann, M. 2003. CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J. Immunol. Meth. 278:79-93.
8. Lehmann, P. V., Cardinaux, F., Appella, E., Muller, S., Falcioni, F., Adorini, L., and Nagy, Z. A. 1989. Inhibition of T-cell response with peptides is influenced by both peptide-binding specificity of major histocompatibility complex molecules and susceptibility of T-cells to blocking. Eur. J. Immunol. 19:1071-1077.
9. Maecker, H. T., Hassler, J., Payne, J. K., Summers, A., Comatas, K., Ghanayem, M., Morse, M. A., Clay, T. M., Lyerly, H. K., Bhatia, S., Ghanekar, S. A., Maino, V. C., Delarosa, C., and Disis, M. L. 2008. Precision and linearity targets for validation of an IFN? ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol. 9:9.
10. Targoni, O. S., and Lehmann, P. V. 1998. Endogenous myelin basic protein inactivates the high avidity T-cell repertoire. J. Exp. Med. 187:2055-2063.
11. van der Burg, S. H. 2008. Therapeutic vaccines in cancer: Moving from immunomonitoring to immunoguiding. Expert Rev. Vaccines 7:1-5.
12. Wills, M., Carmichael, A., Mynard, K., Jin, X., Weekes, M., Plachter, B., and Sissons, J. 1996. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: Frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J. Virol. 70:7569-7579.